Exploration of Oxetanes and Azetidines in Structure-Based Drug Design

Mohana Krishna Ramisetty; Vikas Yadav; Kesavan Venkitasamy; Sundarababu Baskaran

doi:10.1055/a-2698-0616

Synlett, Table of Contents

Synlett
DOI: 10.1055/a-2698-0616

Letter

Published as part of the Special Issue dedicated to Prof. S. Chandrasekaran on his 80th birthday

Exploration of Oxetanes and Azetidines in Structure-Based Drug Design

Authors

Mohana Krishna Ramisetty

¹Chemical Biology Laboratory, Department of Biotechnology, Indian Institute of Technology, Madras, Bhupat and Jyoti Mehta School of Biosciences, Chennai, India (Ringgold ID: RIN37268)

³Department of Chemistry, Indian Institute of Technology, Madras, Chennai, India (Ringgold ID: RIN28754)
Vikas Yadav

²School of Computation and Integrative Sciences, Jawaharlal Nehru University, New Delhi, India
Kesavan Venkitasamy

¹Chemical Biology Laboratory, Department of Biotechnology, Indian Institute of Technology, Madras, Bhupat and Jyoti Mehta School of Biosciences, Chennai, India (Ringgold ID: RIN37268)
Sundarababu Baskaran

³Department of Chemistry, Indian Institute of Technology, Madras, Chennai, India (Ringgold ID: RIN28754)

Abstract

All articles of this category

Abstract

Oxetane and azetidine motifs are widely used in medicinal chemistry to enhance various attributes such as hydrophilicity, metabolic stability, hydrophobicity, and conformational preference. These stable structures are present in numerous bioactive compounds, including FDA-validated therapeutic agents. This study aims to demonstrate the use of oxetane and azetidine ring systems as bioisosteric replacements for isopropyl groups in the development of novel lead candidates. The objective is to improve physicochemical and structural characteristics to facilitate effective molecular optimization, improve pharmacological activity, and simplify synthetic pathways. This can ultimately increase the chances of discovering medication that is more efficient and safer to use. We report the virtual screening of selected 14 approved drugs with a replacement of isopropyl to oxetane and azetidine group transformation, enabling optimization for receptor binding potential and absorption, distribution, metabolism, and excretion (ADME) properties. The results indicate that oxetane alectinib (−6.906 kcal/mol), azetidine procarbazine (−8.083 kcal/mol), azetidine erdafitinib (−7.677 kcal/mol), oxetane anastrozole (−7.454 kcal/mol), azetidine nateglinide (−6.686 kcal/mol), oxetane repaglinide (−7.831 kcal/mol), oxetane nilutamide (−9.649 kcal/mol), and oxetane proguanil (−8.555 kcal/mol) have excellent molecular affinity when compared to their parent molecule. This perspective aims to inspire medicinal chemists to explore the use of oxetane and azetidine moieties in the development of effective drug candidates.

Keywords

Oxetane - Azetidine - Isopropyl group - Drugs - Binding potential - ADME properties

Full Text

References

References
1 Amir M, Qureshi MA, Javed S. J Biomol Struct Dyn 2021; 39: 3934-3947
2 Anwer R, Ahmad N, Al Qumaizi KI, Al Khamees OA, Al Shaqha WM, Fatma T. J Mol Recognit 2017; 30 (1/6) e2599
3 Bachrach SM. J Org Chem 2008; 73: 2466-2468
4 Bauer MR, Di Fruscia P, Lucas SCC. et al. RSC Med Chem 2021; 12: 448-471
5 Brandi A, Cicchi S, Cordero FM. Chem Rev 2008; 108: 3988-4035
6 Bull JA, Croft RA, Davis OA, Doran R, Morgan KF. Chem Rev 2016; 116: 12150-12233
7 Litskan O, Semenchenko S, Lynnyk D. et al. Org Chem Front 2025; 12: 3775-3785
8 Candel FJ, Peñuelas M. Drug Des Dev Ther 2017; 11: 881-891
9 Albitz K, Tóth S, Csókás D. Angew Chem Int Ed 2025; 64: e202416441
10 Das T, Mukhopadhyay C. J Biomol Struct Dyn 2023; 41: 3368-3381
11 Delaney JS. J Chem Inf Comput Sci 2004; 44: 1000-1005
12 Delaney JS. J Chem Inf Comput Sci 2004; 44: 1000-1005
13 Dey S, Basak S, De A. et al. J Chromatogr Sci 2020; 58: 309-322
14 Ding D, Wang M, Wu J-X, Kang Y, Chen L. Cell Rep 2019; 27: 1848-1857
15 Dubois MAJ, Croft RA, Ding Y. et al. RSC Med Chem 2021; 12: 2045-2052
16 Dubois MAJ, Smith MA, White AJP. et al. Org Lett 2020; 22: 5279-5283
17 Evans GB, Furneaux RH, Greatrex B, Murkin AS, Schramm VL, Tyler PC. J Med Chem 2008; 51: 948-956
18 Madhav H, Reddy GS. RSC Med Chem 2024; 15: 1022-1037
19 Ikee Y, Hashimoto K, Kamino M. et al. Chem Pharm Bull 2008; 56: 346-356
20 Mughal H, Szostak M. Org Biomol Chem 2021; 19: 3274-3286
21 Johnson TW, Gallego RA, Edwards MP. J Med Chem 2018; 61: 6401-6420
22 Khan MF, Nahar N, Rashid RB, Chowdhury A, Rashid MA. BMC Complement Altern Med 2018; 18: 48
23 Kumari S, Maurya J, Ramamoorthy A, Sundarrajan S, Lulu S, Arumugam M. Int J Pharm Pharm Sci 2014; 6: 66-69
24 Lonikar N, Choudhari P, Bhusnuare O. J Biomol Struct Dyn 2021; 39: 3515-3522
25 Venkitasamy KJ. J Biomol Struct Dyn 2023; 41: 14638-14650
26 Maetani M, Kato N, Jabor VAP. et al. ACS Med Chem Lett 2017; 8: 438-442
27 Manish M, Mishra S, Anand A, Subbarao N. Comput Biol Med 2022; 150: 106125
28 Moriguchi I, Hirono S, Liu Q, Nakagome I, Matsushita Y. Chem Pharm Bull 1992; 40: 127-130
29 Mugumbate G, Abrahams KA, Cox JAG. et al. PLoS One 2015; 10: 1-10
30 Ono F, Chiba S, Isaka Y. et al. Sci Rep 2020; 10: 1-10
31 Jeffries B, Wang Z, Troup RI. et al. Beilstein J Org Chem 2020; 16: 2141-2150
32 Leelavathi PT, Shankar M, Pasha TY, Ramesh B, Sekar M. Pharm Res 2023; 7: 000282
33 Parsy C, Alexandre FR, Brandt G. et al. Bioorg Med Chem Lett 2014; 24: 4444-4449
34 Pastewska M, Bednarczyk-Cwynar B, Kovačević S. et al. J Chromatogr A 2021; 1656: 462552
35 Pletsa V, Valavanis C, van Delft JH, Steenwinkel MJ, Kyrtopoulos SA. Carcinogenesis 1997; 18: 2191-2196
36 Raffa RB, Pergolizzi JV. Pharmacol Pharm 2019; 10: 465-473
37 Girdhar N, Yadav V, Kumari N, Subbarao N, Krishnamachari A. Biomol Struct Dyn. 2024
38 Rogers-Evans M, Knust H, Plancher JM. et al. Chimia 2014; 68: 492-499
39 Ryckmans T, Edwards MP, Horne VA. et al. Bioorg Med Chem Lett 2009; 19: 4406-4409
40 Sachdeva H, Khaturia S, Saquib M. et al. Appl Biochem Biotechnol 2022; 194: 6438-6467
41 Shaker B, Yu MS, Lee J, Lee Y, Jung C, Na D. J Microbiol 2020; 58: 235-244
42 Raturi A, Yadav V, Hoda N, Subbarao N, Chaudhry SA. J Biomol Struct Dyn 2023; 42: 585-611
43 Dubois MAJ, Smith MA, White AJP. et al. Org Lett 2020; 22: 5279-5283
44 Shweta M, Rashmi D. J Drug Delivery Ther 2019; 9: 266-369
45 Skinner-Adams TS, Fisher GM, Riches AG. et al. Commun Biol 2019; 2: 1-7
46 Stepan AF, Karki K, McDonald WS. et al. J Med Chem 2011; 54: 7772-7783
47 Su M, Yang Q, Du Y. et al. J Chem Inf Model 2019; 59: 895-913
48 Verma J, Subbarao N. J Biomol Struct Dyn 2022; 30: 127457
49 Surleraux DLNG, Tahri A, Verschueren WG. et al. J Med Chem 2005; 48: 1813-1822
50 Suvannang N, Nantasenamat C, Isarankura-Na-Ayudhya C, Prachayasittikul V. Molecules 2011; 16: 3597-3617
51 Butler MS. J Nat Prod 2004; 67: 2141-2153
52 Tian X, He Y, Zhou J. Front Pharmacol 2015; 6: 57
53 Wuitschik G, Carreira EM, Wagner B. et al. J Med Chem 2010; 53: 3227-3246
54 Zheng X, Gao L, Wang L. et al. J Med Chem 2019; 62: 6315-6329
55 Zheng X, Liang C, Wang L. et al. J Med Chem 2018; 61: 10228-10241
56 Daina A, Michielin O, Zoete V. Sci Rep 2017; 7: 42717
57 Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. J Comput Aided Mol Des 2013; 27: 221-234
58 Agrawal A, Chanana P. J Biomol Struct Dyn 2023; 20: 1201-1214
59 Chen P, Lee NV, Hu W. et al. Mol Cancer Ther 2016; 15: 2273-2281
60 Sakamoto H, Tsukaguchi T, Hiroshima S. et al. Cancer Cell 2011; 19: 679-690
61 Boerma LJ, Xia G, Qui C. et al. J Biol Chem 2014; 289: 814-826
62 Raies AB, Bajic VB. WIREs Comput Mol Sci 2016; 6: 147-172
63 Banerjee P, Eckert AO, Schrey AK, Preissner R. Nucleic Acids Res 2018; 46: W257-W263
64 Martin TM, Harten P, Venkatapathy R, Das S, Young DM. Toxicol Mech Methods 2008; 18: 251-266
65 Banks JL, Beard HS, Cao Y. et al. J Comput Chem 2005; 26: 1752-1780
66 Abraham MJ, Murtola T, Schulz R. et al. SoftwareX 2015; 1–2: 19-25
67 Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Proteins: Struct, Funct, Bioinf 2006; 65: 712-725
68 Sousa da Silva AW, Vranken WFACPYPE. Notes 2012; 5: 367
69 Mark P, Nilsson L. J Phys Chem A 2001; 105: 9954-9960
70 Mahoney MW, Jorgensen WL. J Chem Phys 2000; 112: 8910-8922
71 Kashif M, Subbarao N. J Biomol Struct Dyn 2023; 41: 13914-13922
72 Kollman PA, Massova I, Reyes C. et al. Acc Chem Res 2000; 33: 889-897
73 Kumari R, Kumar R, Lynn A. J Chem Inf Model 2014; 54: 1951-1962
74 Richmond TJ. J Mol Biol 1984; 178: 63-89
75 Kirchmair J, Williamson MJ, Tyzack JD. et al. J Chem Inf Model 2012; 52: 617-648
76 Wang Y, Xing J, Xu Y. et al. Quart Rev Biophys 2015; 48: 488-515
77 Duchowicz PR, Talevi A, Bellera C, Bruno-Blanch LE, Castro EA. Bioorg Med Chem 2007; 15: 3711-3719
78 Leeson P, Springthorpe B. Nat Rev Drug Discovery 2007; 6: 881-890
79 Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Adv Drug Delivery Rev 1997; 23: 3-25
80 Coates JT, Lindsley CW, McKinney D, Rhodes GR. US Patent Application US 2010/0160340 A1 2010
81 Chen S, Liu Z, Xu B, Gao Y. WO 2017/114512 A1 2017 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017114512
82 Yadav V, Kashif M, Kamali Z, Gourinath S, Subbarao N. Molr Inf 2025; 44: 1-13

Supplementary Material

Supplementary Material (PDF) (opens in new window)